Sazerac tried the front door in April. Brown-Forman’s board shut it in May. So over the weekend Sazerac executive chairman Mark Brown and CEO Jake Wenz sent a letter past the board to Brown-Forman’s directors and shareholders directly, asking them to reconsider the same all-cash $32 a share — a 23% premium to Friday’s close, roughly $15 billion — and dangling more. “Sazerac stands ready to improve the terms of our offer, should the board engage with us,” the letter said, per Bloomberg, which reviewed it.
Brown-Forman’s answer, issued Sunday, did not say the price was too low. It said the proposal was “not actionable.” Wolf Pen Branch, LP — the vehicle through which Brown family members hold the majority of the Class A voting shares — reached the same conclusion, and said the company is “well-positioned to deliver long-term value for all shareholders.” The family has run this business since 1870. BF.B traded up nearly 4% at midday and closed up about 1.5%.
“Not actionable” is corporate for there is no mechanism here. Brown-Forman’s Class B shares — the ones the public owns, the ones in the index funds — carry no vote on this. A tender offer needs shares that can be tendered into a change of control. Those shares are Class A, and they are spoken for.
The price of a permission-based stock
What makes this more than a governance footnote is the state of the underlying business. Fiscal 2026 net sales fell 1% on a reported basis to $3.9 billion and were flat organically. Fourth-quarter sales rose 2% to $912 million, but earnings per share dropped 62% year over year to 12 cents. Management guided fiscal 2027 to roughly flat organic sales and organic operating income down 3% to 5%. The stock has traded around $26 this month, some 48% below its 52-week high of $49.89.
So the Class B holder’s position is this: a broken multi-year chart, a guide that promises less next year than this year, and an all-cash bid at a 23% premium sitting on the table that they have no legal instrument to accept. The discount you pay for a controlled company isn’t theoretical. Monday was the invoice.
Our take: Sazerac isn’t negotiating with a board, it’s negotiating with a family’s sense of timing — and Sazerac is private, so it can wait as long as they can. Going public with the letter is the only lever a bidder has left when the vote is unavailable: it can’t win a proxy fight, but it can make every Class B holder do the arithmetic out loud, and it can make the next disappointing quarter feel expensive to the people who chose to own it. Compare Utz, where the founding family took the 91% premium and kept half the business. Same structure, opposite instinct. Structure isn’t destiny; the family’s appetite is.
What to watch
- Whether Sazerac names a higher number in public. Saying “we’d improve terms” costs nothing. Printing $36 forces the family to reject a specific figure in front of its own minority holders — the move Prologis ran on Segro’s board this month.
- Cracks in Wolf Pen Branch. Family blocks hold until an estate, a divorce or a generational split makes liquidity urgent. Watch Class A ownership filings, not the earnings deck.
- The next quarter. Guidance already points down. A miss against a lowered bar is the argument Sazerac cannot make for itself.
- The Class A/Class B spread. It is the cleanest live read on what the market thinks control is worth here — and whether anyone believes this ends in a deal.
- Boards that do say yes. Contrast is instructive: argenx paid a 41% premium for Forte Biosciences and closed it in a morning. Willing seller, actionable proposal.
The broader tape gave this nothing to hide behind. The S&P 500 finished Monday up 1.20 points at 7,413.18 — a rounding error. On a day when the index said nothing, a $15 billion bid got refused by people who never had to take a call.